Iovance Biotherapeutics, Inc. (IOVA) Financials

Iovance Biotherapeutics generated about $325 million in revenue over the trailing twelve months. Revenue has grown at roughly 1,388.7% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Iovance Biotherapeutics reported about -$290 million in net loss over the trailing twelve months, a net margin of roughly -89.1%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

Iovance Biotherapeutics runs a gross margin of about 48.4%, an operating margin of about -92.7%, a net margin of about -89.1%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

Iovance Biotherapeutics's revenue has compounded at roughly 1,388.7% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside IOVA's margins and free cash flow. This is analysis from SEC filings, not investment advice.